Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Genie29jon Nov 13, 2020 7:49pm
122 Views
Post# 31900109

RE:What Comes Next ?

RE:What Comes Next ?

I think the drop is expected for a variety of reasons

1. those that bought at 10-15¢ made a great profit. Any stock that pops like that will have a sell off
 
 2. There still is no tangible news for the products. The products are the true bread and butter and will be the needle movers

3. the device will yield far greater than $1. $1 puts the value of the device at $35M in that case. If this product is commercialized in Asia, USA, Eurpoe, this should easily yield $5 (minimum). They have invested millions in this product, no chance they do this for break even 

while I think the next couple months will be quiet, as long as they are working hard and fast with this new funding I am perfectly cool with that.
 

one last nugget I liked from today's tweet from RepliCel was this last eat news has peaked the interest of other investors... this could be just the start for a great 2021

<< Previous
Bullboard Posts
Next >>